🧪 Zydus Launches India’s First Trivalent Influenza Vaccine – VaxiFlu™

Zydus Lifesciences Ltd. (NSE: Zyduslife, BSE: 532321) has introduced VaxiFlu™, India’s first trivalent influenza vaccine, aligning with the World Health Organization’s (WHO) 2025–26 recommendations. 🌍 Why This Matters Seasonal influenza causes 3–5 million severe cases annually with up to 650,000 respiratory deaths worldwide. Vulnerable populations – infants, elderly, and people with chronic conditions – remain at highest risk. WHO and India’s National Centre for Disease Control (NCDC) now recommend the trivalent vaccine since the B/Yamagata strain has not circulated globally since 2020. 💉 VaxiFlu™ Key Facts Formulation: Trivalent (H1N1, H3N2, B/Victoria strains). Age Group: Recommended for individuals 6 months and above. Precision: Updated annually as per WHO surveillance data. 🗣️ Expert Views Dr. Parvaiz Koul (Pulmonology & WHO Advisor): “The trivalent formulation is the most scientific choice since the B/Yamagata strain hasn’t been in circulation for 5 years. Nearly 40 countries, including the US, have already transitioned.” Dr. Sharvil Patel, MD, Zydus Lifesciences: “Vaccines are essential to preventive health. With VaxiFlu™, we align with global guidelines to reduce vaccine-preventable diseases in high-risk groups.” 🧭 Strategic Impact First-mover advantage: Zydus becomes India’s pioneer in trivalent influenza vaccines. Global alignment: Follows WHO, CDC, and NCDC guidance. Preventive healthcare boost: Strengthens India’s vaccine ecosystem at a time of rising infectious disease threats. Zydus continues to expand its innovation-led healthcare portfolio, with over 1,500 scientists in R&D and a mission to transform lives through accessible, science-backed healthcare solutions. 🔔 Disclaimer: This post is for informational purposes only and not investment advice. Please consult healthcare professionals for medical guidance. 👉 Follow for more healthcare, pharma, and market insights.